pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The two antibodies also were fully active against Alpha, Beta, Gamma, and Delta variants. 2 subtypes.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

Pharmaceutical Technology

AUGUST 12, 2022

The concept behind this form of treatment is that the introduction of these cells will enhance the immune response to disease, often through bioengineering the immune cells to have improved functionality and characteristics, such as longer half-lives. Overall, the global CAR-T cell market for all indications was worth $1.7

Development 130

Development Drugs Immune Response Marketing 130

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Cell-Based Immunotherapy vs. Immune Biologics. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Roots Analysis

FEBRUARY 23, 2024

Imagine a world where scientists work together to create special “soldiers” in our bodies called antibodies. Sometimes, scientists ask for help from experts who are really good at finding and designing these antibodies. What are the steps involved in an antibody discovery project? These heroes help to fight diseases.

Antibody 40

Antibody Research Marketing Scientist 40

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. Challenges and Future Directions: Despite their immense promise, biologics are not without challenges.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

XTalks

MAY 7, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first, “original” strain of SARS-CoV-2. In preclinical studies, NVX-CoV2373 induced antibodies that blocked the binding of the coronavirus spike protein to cellular receptors and provided protection from infection and disease.

Protein 97

Protein Vaccine Vaccination Trials 97

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. and Australia.

Protein 52

Protein Vaccine Vaccination Immune Response 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccine Vaccination 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. It’s all part of a deep-seated commitment to innovation and its role as the company’s growth engine. I’m very excited to be leading the next phase in Grifols innovation.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

NOVEMBER 30, 2023

Preclinical data demonstrated that HB-500 was well-tolerated, eliciting robust, high-quality and enduring immune responses, including antigen-specific T cells and antibodies, in non-human primates. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses.

Protein 52

Protein Vaccine Vaccination Antibody 52

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Non-COVID-19-Related.

Immune Response 52

Immune Response Antibody Trials Clinical Trials 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. Monoclonal Antibodies Monoclonal antibodies are lab-engineered immune system proteins.

Vaccine 52

Vaccine Vaccination Protein Antibody 52

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. Editor’s Note : Sanofi previously entered into an agreement with Merck & Co. About THOR-707 (SAR444245).

Immune Response 52

Immune Response Engineer Antibody Genetics 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. and Australia.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccine Vaccination Trials 40

pharmaphorum

JANUARY 7, 2021

Used with widely available PET scan technology, ImaginAb’s technology allows doctors to track the T-cell immune response to cancer in real time and it has already picked up a multi-party deal involving Pfizer, AstraZeneca and Takeda.

Immune Response 53

Immune Response Doctor Doctors Pharma Companies 53

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71.

Vaccine 53

Vaccine Vaccination Research Trials 53

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

pharmaphorum

OCTOBER 12, 2022

Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Debiopharm is interested in innovative therapeutic platforms for tomorrow,” Gibbs says. “We

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

NOVEMBER 29, 2022

From a better understanding of the tumor microenvironment to exciting advances in treatment like activated cell therapies and bispecific antibodies, one could wonder where the next therapeutic revolution in immuno-oncology (IO) will come from. T cells are known to mediate anti-tumor immune responses. NT-I7 (efineptakin alfa).

Clinical Trials 105

Clinical Trials Clinical Trials Trials Engineer 105

pharmaphorum

JANUARY 4, 2023

The University of Michigan spinoff’s NanoDisc technology relies on the use of synthetic, high-density lipoproteins that can be engineered to carry a payload of antigens, presenting them for recognition by the immune system – specifically, dendritic cells within lymph nodes.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease.

Clinical Development 52

Clinical Development Vaccine Vaccination Development 52

pharmaphorum

SEPTEMBER 7, 2022

.” Roche’s activity in this area is represented by RG6279, an anti-PD-1 antibody fused to an engineered, variant form of IL-2 which is in phase 1 clinical testing.

Immune Response 52

Immune Response Engineer Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 6, 2021

ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. About ImaginAb. ImaginAb Inc. is biotechnology company focused on developing radiopharmaceutical imaging and therapy agents.

Licensing 52

Licensing Licensing Clinical Trials Clinical Trials 52

XTalks

MAY 24, 2024

.” XTALKS WEBINAR: AI-based Antibody Therapeutics Developability Assessment and Its Engineering Live and On-Demand: Friday, June 21, 2024, at 10am EDT (4pm CEST/EU-Central) Register for this webinar today to learn how AI can be used to improve developability screening of antibody therapeutics and optimization of antibody candidates.

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

The Pharma Data

AUGUST 9, 2021

Dr Munir said: “Our studies demonstrate that induction of a local immune response at the point of entry of SARS-CoV-2 has the potential to not only limit clinical disease, but also – and perhaps even more importantly – virus transmission from infected to uninfected individuals.”

Vaccine 52

Vaccine Vaccination Immune Response Scientist 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. This press release features multimedia. Graphic: Business Wire).

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

JANUARY 17, 2021

One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans. Standard mice may develop anti-drug antibodies (ADA), which can neutralize the therapeutic or even trigger anaphylaxis.

Genetic Engineering 40

Genetic Engineering Genetics Engineer Immune Response 40

The Pharma Data

APRIL 22, 2023

However, many of those therapies cause severe side effects in different parts of the body, including the immune system itself, and thus carry significant health risks. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

The Pharma Data

JANUARY 22, 2021

iosBio has claimed the OraPro platform enables oral delivery of thermally-stable, viral vector vaccines, which are engineered to withstand temperatures of up to 50°C. When multiple mutations occur at the receptor-binding domain of the spike protein, it renders antibodies ineffective.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

The Pharma Data

JUNE 25, 2021

The CDC has defined Variant of Interest (VoI) as a variant with genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, or predicted increase in transmissibility or disease severity. BARDA is providing up to $1.75 About NVX-CoV2373.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

The Pharma Data

OCTOBER 21, 2020

“We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? We believe that ADI-001 offers the opportunity for on demand treatment, selective tumor targeting, innate and adaptive anti-tumor immune response, and durable activity in patients. About Adicet.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

XTalks

FEBRUARY 29, 2024

These innovative molecules are engineered by combining two or more functional domains from different proteins into a single, cohesive unit, enabling them to perform multiple biological activities simultaneously.

Protein 94

Protein Development Clinical Trials Clinical Trials 94

The Pharma Data

DECEMBER 20, 2020

platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec. It has been generated using Transgene’s Invir.IO

Trials 40

Trials Antibody Clinical Trials Clinical Trials 40